Regensight’s transformative innovation for the definitive cure of keratoconus

The Regensight’s Theranostics (a new paradigm of  therapy guided by diagnostics), is going to halt keratoconus progression with certainty. Keratoconus is primary cause of corneal transplant in young adults worldwide (prevalence: 1% – 2%, about 100 million people). The innovation was presented today at the Spazio Attivo di Lazio Innova of the Roma Tecnopolo together with the interim outcome  of the ongoing clinical investigation, which will end in early 2024. The innovative Regensight platform will be ready for the benefit of all young patients suffering from keratoconus by next summer.